NEW YORK – The European Medicines Agency (EMA) granted conditional approval on Wednesday for trastuzumab deruxtecan (Daiichi Sankyo/AstraZeneca's Enhertu) as a treatment for patients with metastatic, HER2-positive breast cancer who have previously received two or more anti-HER2 treatments.